Thus, we provide evidence for the therapeutic role of pan PPAR-iMSC-EVs in NASH via its anti-steatotic, anti-inflammatory, and tissue-regenerative function. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatohepatitis.